09Oct
Caremark Round II: Beware Red Flags in Drug Development
On October 1, 2019, the Delaware Court of Chancery applied the Delaware Supreme Court’s recent decision on Caremark board oversight claims in the context of operating in a highly regulated industry to allow derivative claims to proceed against the...
By:
Goodwin
Related
It is the rare construction project that is completed without any change in the work. In most sophis...
Read More >
This is the tenth in a series of articles about Best Practices for Plan Sponsors. To be clear, “be...
Read More >
A plan’s definition of “compensation” tends to be one of the trickier aspects of 401(k) administr...
Read More >
The megadeals of 2019 may be off the table for now, but deal activity across healthcare and pharmace...
Read More >
The Coronavirus and Its Impact on Those Traveling from China - On January 31, 2020, in response to...
Read More >
Despite considerable volatility and uncertainty, 2020 has been an extraordinary year for the London ...
Read More >